Melasma is one of the most stubborn pigmentation conditions in aesthetic medicine. It doesn’t respond reliably to a single hero ingredient, it flares with sun and hormones, and it tends to come back even after months of disciplined topical care. Oral tranexamic acid, a prescription medication originally developed to control bleeding, has emerged over the last decade as one of the most effective adjunctive treatments for melasma, and at Nervana Medical in Sandy, UT, it’s one of the tools we consider when topical therapy alone isn’t getting the job done.
This post walks through what oral tranexamic acid actually does, what the research shows, how it’s dosed, and, just as important, who shouldn’t take it. Because oral TXA is a systemic prescription, it belongs in a setting where the same provider who is treating the pigmentation can also screen the medical history. That’s exactly the integrative model we work in.
What Oral Tranexamic Acid Is (and Why It Works for Melasma)
Tranexamic acid is an antifibrinolytic, a medication that interferes with the breakdown of fibrin clots. It’s been used in surgery and heavy menstrual bleeding for decades. Its role in melasma is more recent and more interesting.
Melasma is driven by overactive melanocytes that respond aggressively to UV exposure, heat, inflammation, and hormonal signals. Research suggests oral TXA works on melasma by reducing the interaction between melanocytes and the surrounding keratinocytes and mast cells that keep telling them to produce pigment. It also appears to dampen the vascular component of melasma, the often-overlooked redness and dilated vessels that sit underneath the brown.
In other words, it doesn’t bleach pigment. It quiets the signaling that drives the pigment in the first place.
The Evidence: What the Studies Actually Show
Oral TXA has substantially more high-quality evidence behind it than most trending melasma treatments. A few of the studies that anchor current practice:
- A large retrospective analysis of 561 melasma patients found an 89.7% improvement rate, with response usually visible within two months of starting treatment.
- A double-blind, placebo-controlled randomized trial showed oral TXA at 250 mg twice daily produced a 49% reduction in modified MASI scores at three months, compared to 18% with placebo. Patients with more severe melasma saw the biggest benefit.
- When added to a triple-combination topical (hydroquinone-based), oral TXA dramatically outperformed topical therapy alone: 65.6% of patients achieved greater than 75% improvement at 12 weeks, versus 27.1% on topical only, and the relapse rate dropped from roughly 64% to 18%.
The consistent pattern across studies: oral TXA is most powerful as an adjunct to a good topical regimen, not as a stand-alone fix. It also works at lower doses than people often assume.
Dosing and Treatment Course
The dosing that shows up most often in the literature is conservative:
- 250 mg twice daily (500 mg/day) for 8 to 12 weeks
- 500 mg twice daily (1,000 mg/day) for 8 to 12 weeks
Head-to-head studies have not shown a meaningful advantage to the higher dose. A 2023 randomized trial comparing 250 mg twice daily to 500 mg twice daily found nearly identical response rates, with benefit sustained for 12 weeks after stopping in both groups. The takeaway: start low, expect early visible change within about 8 weeks, and reassess at 12.
Most patients in our experience do best on a defined course rather than open-ended use: 12 weeks of oral TXA layered onto a sun-protection-and-topical foundation, then a maintenance plan that may include chemical peels, microneedling, or a topical-only holding pattern. Our chemical peels in Sandy, UT program is a common next step once the pigment has been calmed pharmacologically.
Who Should (and Shouldn’t) Take Oral TXA
This is where having an actual medical practice behind the prescription matters. Oral TXA is well tolerated for most people. The largest retrospective series reported side effects in about 7% of patients, mostly transient GI symptoms like heartburn or nausea. Some patients report lighter periods, headache, or mild muscle aches.
The serious concern is thromboembolic risk. TXA is an antifibrinolytic, so any patient with a personal or family history of clotting disorders requires careful screening. Before prescribing, we look at:
- Personal or family history of DVT, PE, or stroke
- Known hypercoagulable conditions (Factor V Leiden, protein S or C deficiency, antiphospholipid syndrome)
- Synthetic Hormones / oral contraception
- Renal function
- Smoking status and cardiovascular history
Oral TXA is contraindicated in patients with active thromboembolic disease, significant renal impairment, or certain hormonal-cancer histories. This isn’t a fill-a-script-and-send-them-out medication, and it shouldn’t be.
Why Oral TXA Fits Best in an Integrative Practice
Melasma is rarely just a skin problem. It’s hormonal, inflammatory, sun-driven, and often vascular. A patient walking in with stubborn melasma usually benefits from a conversation that touches all of those, not just a tube of cream.
Because Nervana Medical is an integrative med spa in Utah that combines aesthetics with hormone replacement therapy, nutrition, and medical care under one roof, we can treat melasma the way it actually behaves. That means screening hormonal contributors, addressing skin barrier and inflammation, prescribing oral TXA when it’s appropriate, and layering in the right procedural treatments at the right time. A patient on combined oral contraceptives with worsening melasma is a very different case than a postmenopausal patient on bioidentical hormones, and the plan should reflect that.
This is the kind of considered, anatomy-first, whole-person care that’s hard to find at a pure injection clinic.
Frequently Asked Questions
Is oral tranexamic acid safe for melasma?
For most healthy patients without a personal or family history of clotting disorders, oral TXA at 250 to 500 mg twice daily for 8 to 12 weeks is well tolerated. The most common side effects are mild GI symptoms. Anyone considering it needs a medical screening for thromboembolic risk, current hormonal medications, and renal function before starting.
How long until I see results from oral TXA for melasma?
Most patients see visible improvement within about 8 weeks, with peak response around 12 weeks. Research shows the effect builds progressively across the treatment course rather than appearing all at once.
Does melasma come back after stopping oral tranexamic acid?
It can. Relapse rates of around 27% have been reported, though some patients hold their improvement for months after stopping, especially when oral TXA was paired with consistent topical therapy and strict sun protection. Maintenance matters as much as the initial course.
Can I take oral TXA if I’m on birth control or HRT?
It depends on the specific medication and your individual risk profile. Combined estrogen-containing contraceptives can raise clotting risk on their own, so we evaluate the combination carefully before prescribing. This is exactly the conversation we have during a melasma consult.
Does oral TXA replace topical melasma treatment?
No. The strongest evidence supports oral TXA as an adjunct to a good topical regimen, typically a hydroquinone-based combination, plus daily sun protection. It works best layered on, not used alone.
Book a Consultation in Sandy, UT
If topical therapy hasn’t moved the needle on your melasma, or if you’ve been chasing the same spots for years without a real plan, a proper assessment is the place to start. To talk through whether oral tranexamic acid, in-office treatments, or a combination is the right fit for you, book a consultation at Nervana Medical in Sandy, UT.
References
- Lee HC, Thng TGS, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis. J Am Acad Dermatol. 2016;75(2):385-392. (561 patients; 89.7% improved with response within 2 months; relapse 27.2%; adverse events 7.1%, including one DVT in a patient later found to have familial protein S deficiency.)
- Del Rosario E, Florez-Pollack S, Zapata L Jr, et al. Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma. J Am Acad Dermatol. 2018;78(2):363-369. (49% mMASI reduction with TXA vs 18% with placebo at 3 months; severe melasma responded most.)
- Minni K, Poojary S. Efficacy and safety of oral tranexamic acid as an adjuvant in Indian patients with melasma: a prospective, interventional, single-centre, triple-blind, randomized, placebo-control, parallel group study. J Eur Acad Dermatol Venereol. 2020;34(11):2636-2644. (TXA plus fluocinolone-based triple-combination cream vs cream alone: 65.6% vs 27.1% marked improvement at 12 weeks; recurrence 18.03% vs 64.4% at 24 weeks.)
- A randomized open-label study to compare two different dosage regimens of oral tranexamic acid in treatment of moderate-to-severe facial melasma. Br J Dermatol. 2023;188(Suppl 4):ljad113.098. (Conference abstract; mMASI-75 at 12 weeks comparable between 250 mg and 500 mg twice-daily groups, with improvement maintained 12 weeks after discontinuation.)